公开(公告)号：US20180002435A1

公开(公告)日：2018-01-04

申请号：US15546630

申请日：2016-01-25

Applicant: Cellectis ,  RINAT NEUROSCIENCE CORPORATION

Inventor： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC: C07K16/28 ,  C07K14/705 ,  G01N15/10 ,  G01N15/14 ,  C12N5/0783 ,  C07K14/725 ,  G01N15/00

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20180002427A1

公开(公告)日：2018-01-04

申请号：US15546619

申请日：2016-01-25

Applicant: CELLECTIS

Inventor： Julianne SMITH ,  Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N5/00 ,  C07K16/30 ,  A61K39/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US20240141293A1

公开(公告)日：2024-05-02

申请号：US18540309

申请日：2023-12-14

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N9/22 ,  C12N15/90

CPC classification number: C12N5/0638 ,  A61K35/17 ,  C12N9/22 ,  C12N15/907 ,  C12N2510/00 ,  C12N2750/14143 ,  C12N2830/008

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20200224163A1

公开(公告)日：2020-07-16

申请号：US16340222

申请日：2017-10-19

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: C12N5/0783 ,  A61K35/17 ,  C12N15/90 ,  C12N9/22

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20180171298A1

公开(公告)日：2018-06-21

申请号：US15578946

申请日：2016-06-30

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Jean-Pierre CABANIOLS ,  Julien VALTON

IPC: C12N5/0783 ,  C12N15/63 ,  A61K35/17 ,  A61K45/06 ,  C12N9/22 ,  C07K14/47 ,  C07K14/725 ,  C12N9/12

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K45/06 ,  A61K2039/515 ,  A61K2039/572 ,  C07K14/4703 ,  C07K14/7051 ,  C12N9/12 ,  C12N9/22 ,  C12N15/63 ,  C12N2510/00

Abstract: The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.

公开(公告)号：US20180051089A1

公开(公告)日：2018-02-22

申请号：US15546623

申请日：2016-01-25

Applicant: Cellectis

Inventor： Roman GALETTO ,  Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON ,  Mathieu SIMON

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.

公开(公告)号：US20160333094A1

公开(公告)日：2016-11-17

申请号：US15111441

申请日：2015-01-14

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Julien VALTON

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/705 ,  C07K14/725

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001112 ,  A61K2039/5156 ,  A61K2039/804 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.

Abstract translation: 本发明涉及单链或多链形式的新一代嵌合抗原受体（CAR），其特异性为所需抗原，由来自软骨鱼的单体抗体衍生的VNAR多肽赋予其特异性。 旨在将免疫细胞特异性转向所选择的不希望的恶性细胞的这种CAR是紧凑的，因此特别适用于靶向中空抗原，例如存在于耐药细胞表面的外排泵的离子通道。 本发明包括多核苷酸，编码所述多链CAR的载体和在其表面表达它们的分离细胞，特别是其用于免疫治疗。

公开(公告)号：US20250057952A1

公开(公告)日：2025-02-20

申请号：US18562603

申请日：2022-05-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N15/90

Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

公开(公告)号：US20200237823A1

公开(公告)日：2020-07-30

申请号：US16755082

申请日：2018-03-09

Applicant: CELLECTIS

Inventor： Brian BUSSER ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Laurent POIROT ,  Julien VALTON

IPC: A61K35/17 ,  C07K16/28 ,  C07K16/30

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US20190328783A1

公开(公告)日：2019-10-31

申请号：US16092414

申请日：2017-04-13

Applicant: CELLECTIS

Inventor： Julien VALTON ,  Philippe DUCHATEAU ,  Laurent POIROT ,  Barbra Johnsson SASU ,  Arvind RAJPAL

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85

Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.